vs
AC Immune SA（ACIU）与百特国际（BAX）财务数据对比。点击上方公司名可切换其他公司
百特国际的季度营收约是AC Immune SA的2070.2倍（$3.0B vs $1.4M）。百特国际净利率更高（-37.9% vs -1622.4%，领先1584.5%）。百特国际同比增速更快（458.0% vs 90.1%）
AC Immune SA是一家临床阶段生物制药企业，专注于开发阿尔茨海默病、帕金森病及罕见tau蛋白病等神经退行性疾病的创新疗法与诊断方案，与全球领先药企展开合作，致力于满足神经疾病领域未被满足的临床需求。
百特国际是总部位于美国伊利诺伊州迪尔菲尔德的跨国医疗健康企业，业务布局覆盖全球众多市场，专注于研发、生产及销售各类医疗相关产品与解决方案，为全球医疗机构和患者提供专业可靠的医疗支持。
ACIU vs BAX — 直观对比
营收规模更大
BAX
是对方的2070.2倍
$1.4M
营收增速更快
BAX
高出367.9%
90.1%
净利率更高
BAX
高出1584.5%
-1622.4%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4M | $3.0B |
| 净利润 | $-23.3M | $-1.1B |
| 毛利率 | — | 19.4% |
| 营业利润率 | -1484.5% | -24.5% |
| 净利率 | -1622.4% | -37.9% |
| 营收同比 | 90.1% | 458.0% |
| 净利润同比 | 6.9% | -120.3% |
| 每股收益（稀释后） | — | $-2.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACIUBAX
| Q4 25 | — | $3.0B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | $1.4M | $2.8B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $533.0M | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | $755.7K | $3.8B | ||
| Q1 24 | — | $3.6B |
净利润ACIUBAX
| Q4 25 | — | $-1.1B | ||
| Q3 25 | — | $-46.0M | ||
| Q2 25 | $-23.3M | $91.0M | ||
| Q1 25 | — | $126.0M | ||
| Q4 24 | — | $-512.0M | ||
| Q3 24 | — | $140.0M | ||
| Q2 24 | $-25.0M | $-314.0M | ||
| Q1 24 | — | $37.0M |
毛利率ACIUBAX
| Q4 25 | — | 19.4% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 35.3% | ||
| Q1 25 | — | 32.8% | ||
| Q4 24 | — | 25.0% | ||
| Q3 24 | — | 38.3% | ||
| Q2 24 | — | 37.5% | ||
| Q1 24 | — | 38.6% |
营业利润率ACIUBAX
| Q4 25 | — | -24.5% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | -1484.5% | 6.8% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | -25.5% | ||
| Q3 24 | — | 5.7% | ||
| Q2 24 | -3051.1% | -5.0% | ||
| Q1 24 | — | 5.2% |
净利率ACIUBAX
| Q4 25 | — | -37.9% | ||
| Q3 25 | — | -1.6% | ||
| Q2 25 | -1622.4% | 3.2% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | -96.1% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | -3313.0% | -8.2% | ||
| Q1 24 | — | 1.0% |
每股收益（稀释后）ACIUBAX
| Q4 25 | — | $-2.21 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $0.18 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $0.27 | ||
| Q2 24 | — | $-0.62 | ||
| Q1 24 | — | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.3M | $2.0B |
| 总债务越低越好 | — | $9.5B |
| 股东权益账面价值 | $82.2M | $6.1B |
| 总资产 | $209.2M | $20.1B |
| 负债/权益比越低杠杆越低 | — | 1.55× |
8季度趋势，按日历期对齐
现金及短期投资ACIUBAX
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | $28.3M | $1.7B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | $56.7M | $2.1B | ||
| Q1 24 | — | $3.0B |
总债务ACIUBAX
| Q4 25 | — | $9.5B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $10.4B | ||
| Q3 24 | — | $10.4B | ||
| Q2 24 | — | $10.4B | ||
| Q1 24 | — | $11.1B |
股东权益ACIUBAX
| Q4 25 | — | $6.1B | ||
| Q3 25 | — | $7.2B | ||
| Q2 25 | $82.2M | $7.3B | ||
| Q1 25 | — | $7.1B | ||
| Q4 24 | — | $7.0B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | $135.8M | $7.6B | ||
| Q1 24 | — | $8.2B |
总资产ACIUBAX
| Q4 25 | — | $20.1B | ||
| Q3 25 | — | $21.1B | ||
| Q2 25 | $209.2M | $21.0B | ||
| Q1 25 | — | $21.3B | ||
| Q4 24 | — | $25.8B | ||
| Q3 24 | — | $26.7B | ||
| Q2 24 | $261.3M | $26.3B | ||
| Q1 24 | — | $27.8B |
负债/权益比ACIUBAX
| Q4 25 | — | 1.55× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | 1.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $584.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACIUBAX
| Q4 25 | — | $584.0M | ||
| Q3 25 | — | $237.0M | ||
| Q2 25 | — | $217.0M | ||
| Q1 25 | — | $-193.0M | ||
| Q4 24 | — | $488.0M | ||
| Q3 24 | — | $253.0M | ||
| Q2 24 | — | $115.0M | ||
| Q1 24 | — | $163.0M |
现金转化率ACIUBAX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.38× | ||
| Q1 25 | — | -1.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 4.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACIU
暂无分部数据
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
